Trends over time in adult cannabis use: A review of recent findings

Current Opinion in Psychology, Journal Year: 2021, Volume and Issue: 38, P. 80 - 85

Published: March 21, 2021

Language: Английский

---

Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study

Molecular Psychiatry, Journal Year: 2024, Volume and Issue: 29(8), P. 2587 - 2598

Published: March 14, 2024

Cannabis is the most frequently used illicit drug in United States with more than 45 million users of whom one-third suffer from a cannabis use disorder (CUD). Despite its high prevalence, there are currently no FDA-approved medications for CUD. Patients treated semaglutide, glucagon-like peptide-1 receptor agonist (GLP-1RA) approved treating type 2 diabetes (T2D) and weight management have reported reduced desire to drink smoke. Preclinical studies shown that semaglutide decreased nicotine alcohol consumption. preliminary clinical evidence semaglutide's potential beneficial effects on various substance disorders led us evaluate if it pertained In this retrospective cohort study electronic health records (EHRs) TriNetX Analytics Network, global federated research network approximately 105.3 patients 61 large healthcare organizations US, we aimed assess associations both incident recurrent CUD diagnosis compared non-GLP-1RA anti-obesity or anti-diabetes medications. Hazard ratio (HR) 95% confidence intervals (CI) were calculated 12-month follow-up by comparing propensity-score matched patient cohorts. The population included 85,223 obesity who prescribed medications, findings replicated 596,045 T2D. (mean age 51.3 years, 65.6% women), was associated lower risk prior history (HR: 0.56, CI: 0.42-0.75), 0.62, 0.46-0.84). Consistent reductions seen stratified gender, group, race without Similar T2D when 0.40, 0.29-0.56) 0.66, 0.42-1.03). While these provide benefit real-world populations, further preclinical warranted understand underlying mechanism randomized trials needed support clinically

Language: Английский

---

Substance use and addictive disorders in DSM-5 and ICD 10 and the draft ICD 11

Current Opinion in Psychiatry, Journal Year: 2017, Volume and Issue: 30(4), P. 227 - 237

Published: April 28, 2017

The present review compares and contrasts the diagnostic entities taxonomy of substance use addictive disorders in beta draft Eleventh Revision International Classification Diseases (ICD 11), which was released November 2016, Fifth Edition Diagnostic Statistical Manual Mental Disorders (DSM-5), published mid-2013. Recently papers relevant to these two classification systems are examined. New initiatives diagnosis assessment including addictions neuroclinical noted.The ICD 11 retains dependence as 'master diagnosis' contrast broader heterogeneous concept disorder DSM-5 there is empirical support for coherence alcohol, cannabis, prescribed opioids. Both now include gambling section, with it being transferred from impulse control section. new Internet gaming included a condition further study, grouped 11. Initiatives U.S. National Institutes Health (NIH) highlighting importance capturing neurobiological phases cycle clinical assessment.Although most changes incremental, between 11, inclusion will generate much discussion research.

Language: Английский

---

Cannabis use disorders among adults in the United States during a time of increasing use of cannabis

Drug and Alcohol Dependence, Journal Year: 2019, Volume and Issue: 204, P. 107468 - 107468

Published: Sept. 12, 2019

Language: Английский

---

A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults

Drug and Alcohol Dependence, Journal Year: 2017, Volume and Issue: 177, P. 249 - 257

Published: June 11, 2017

Language: Английский

---